<DOC>
	<DOCNO>NCT01674829</DOCNO>
	<brief_summary>To evaluate safety tolerability MA09-hRPE cellular therapy patient advance dry AMD To evaluate safety surgical procedure use implant MA09-hRPE cell To assess number hRPE cell transplant future study To evaluate exploratory basis potential efficacy endpoint use future study MA09-hRPE cellular therapy .</brief_summary>
	<brief_title>A Phase I/IIa , Open-Label , Single-Center , Prospective Study Determine Safety Tolerability Sub-retinal Transplantation Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial ( MA09-hRPE ) Cells Patients With Advanced Dry Age-related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Adult male female 55 year age . Patient sufficiently good health reasonably expect survival least four year treatment Clinical finding consistent advance dry AMD evidence one area &gt; 250microns geographic atrophy ( define AgeRelated eye Disease Study [ AREDS ] study ) involve central fovea . GA define attenuation loss RPE observe biomicroscopy , OCT , FA . No evidence current prior choroidal neovascularization treat eye The visual acuity ( BCVA ) eye receive transplant well 20/400 . The visual acuity ( BCVA ) eye NOT receive transplant worse 20/400 . Electrophysiological finding consistent advance dry AMD . Medically suitable undergo vitrectomy subretinal injection . Medically suitable general anesthesia wake sedation , need . Medically suitable transplantation embryonic stem cell line : Any laboratory value fall slightly outside normal range review Medical Monitor Investigators determine clinical significance . If determine clinically significant , patient may enrol study . Normal serum chemistry complete blood count [ CBC ] , prothrombin time [ PT ] , activate partial thromboplastin time [ aPTT ] Negative urine screen drug abuse . Negative human immunodeficiency virus ( HIV ) , hepatitis B ( HBV ) , hepatitis C ( HCV ) serology . No history malignancy Negative cancer screen within previous 6 month : complete history &amp; physical examination ; dermatological screening exam malignant lesion ; negative fecal occult blood test &amp; negative colonoscopy within previous 7 year ; negative chest roentgenogram ( CXR ) ; normal CBC &amp; manual differential ; negative urinalysis ( U/A ) ; normal thyroid exam ; male , normal testicular examination ; digital rectal examination ( DRE ) prostate specific antigen ( PSA ) ; female , normal pelvic examination Papanicolaou smear ; If female , normal clinical breast exam , negative mammogram . If female childbearing potential , willing use two effective form birth control study . If male , willing use barrier spermicidal contraception study . Willing defer future blood , blood component tissue donation . Able understand willing sign inform consent Presence active inactive CNV eye treat . Presence history retinal dystrophy , retinitis pigmentosa , chorioretinitis , central serious choroidopathy , diabetic retinopathy retinal vascular degenerative disease ARMD . History optic neuropathy . Macular atrophy due cause AMD . Presence glaucomatous optic neuropathy study eye , uncontrolled IOP , use two agent control IOP ( acetazolamide , beta blocker , alpha1agonist , prostaglandin , anhydrous carbonic inhibitor ) Cataract sufficient severity likely necessitate surgical extraction within 1 year . History retinal detachment repair study eye . Axial myopia great 8 diopter Axial length great 28 mm . History myocardial infarction previous 12 month . History diabetes mellitus . History cognitive impairment dementia may impact patient ability participate inform consent process appropriately complete evaluation . Any immunodeficiency . Any current immunosuppressive therapy intermittent low dose corticosteroid . Alanine transaminase/aspartate aminotransferase ( ALT/AST ) &gt; 1.5 time upper limit normal know liver disease . Renal insufficiency , define creatine level &gt; 1.3 mg/dL . A hemoglobin concentration le 10 gm/dL , platelet count le 100k/mm3 absolute neutrophil count le 1000/mm3 study entry . Serologic evidence infection Hepatitis B , Hepatitis C , HIV . Current participation clinical trial . Participation within previous 6 month clinical trial drug ocular systemic administration . Any sightthreatening ocular disease . Any history retinal vascular disease ( compromised bloodretinal barrier . Glaucoma . Uveitis intraocular inflammatory disease . Significant lens opacity medium opacity . Ocular lens removal within previous 3 month . Ocular surgery study eye previous 3 month If female , pregnancy lactation . Any medical condition , , Investigator 's judgment , interfere patient 's ability comply protocol , compromise patient safety , interfere interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>